Lexicon Pharmaceuticals Stock News

THE WOODLANDS, Texas (AP) _ Lexicon Pharmaceuticals Inc. (LXRX) on Monday reported a loss of $25.6 million in its fourth quarter. On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 17 cents. The drugmaker posted revenue of $14,000 in the period. For the year, the company reported that its loss widened to $87.8 million, or 60 cents per share. Revenue was reported as $298,000. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LXRX at https://www.zacks.com/ap/LXRX

Lexicon Pharmaceuticals press release (LXRX): Q4 GAAP EPS of -$0.17 beats by $0.01.Revenue of $0.01M (-95.0% Y/Y).

Conference Call and Webcast at 8:00 am Eastern Time Conference Call and Webcast at 8:00 am Eastern Time

Conference Call and Webcast at 8:00 am Eastern Time Conference Call and Webcast at 8:00 am Eastern Time

Resubmission to Correct Recently-Identified Technical Issue

Lexicon Pharmaceuticals, Inc.'s (LXRX) CEO Lonnel Coats on Q4 2021 Results - Earnings Call Transcript

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ: LXRX ) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (NASDAQ: PRAX ) is likely to report earnings for its fourth quarter. • Blackstone Secured (NYSE: BXSL ) is likely to report quarterly earnings at $0.59 per share on revenue of $171.69 million. • Mersana Therapeutics (NASDAQ: MRSN ) is estimated to report earnings for its fourth quarter. • Partner Communications Co (NASDAQ: PTNR ) is expected to report earnings for its fourth quarter. • Daqo New Energy (NYSE: DQ ) is expected to report quarterly earnings at $4.58 per share on revenue of $698.65 million. • Easterly Government Props (NYSE: DEA ) is likely to report quarterly earnings at $0.10 per share on revenue of $72.20 million. • Aurinia Pharmaceuticals (NASDAQ: AUPH ) is expected to report earnings for its fourth quarter. • Kosmos Energy (NYSE: KOS ) is estimated to report quarterly earnings at $0.15 per share on revenue of $380.

THE WOODLANDS, Texas, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2021 financial results on Monday, February 28, 2022 before th

THE WOODLANDS, Texas, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2021 financial results on Monday, February 28, 2022 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss its financial and operating results and to provide a general business update.

THE WOODLANDS, Texas, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2021 financial results on Monday, February 28, 2022 before the

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks

Lexicon Pharmaceuticals highlighted certain potential value drivers for 2022 at the 40th Annual J.P. Morgan Healthcare Conference

THE WOODLANDS, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the 40th

Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.

Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.